These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 6162994)

  • 21. Localization of co-resistance to streptomycin, kanamycin, capreomycin, and tuberactinomycin in core particles derived from ribosomes of viomycin-resistant Mycobacterium smegmatis.
    Yamada T; Mizuguchi Y; Suga K
    J Antibiot (Tokyo); 1976 Oct; 29(10):1124-6. PubMed ID: 62857
    [No Abstract]   [Full Text] [Related]  

  • 22. [Activities of rifampicin, capreomycin, viomycin or kanamycin against Mycobacterium tuberculosis isolated from tuberculosis patients].
    Endo K
    Jpn J Antibiot; 1970 Aug; 23(4):387-9. PubMed ID: 4321638
    [No Abstract]   [Full Text] [Related]  

  • 23. The genetic basis of cross-resistance between streptomycin, viomycin and kanamycin of tubercle bacilli and atypical mycobacteria.
    Bönicke J; Bönicke R
    Bull Int Union Tuberc; 1970 Jun; 43():229-34. PubMed ID: 4316621
    [No Abstract]   [Full Text] [Related]  

  • 24. [Studies on resistance of tubercle bacilli to reserve drugs. II. Resistance to viomycin and kanamycin in experimenta tuberculosis in guinea pigs].
    Janowiec M
    Gruzlica; 1966 Oct; 34(10):903-6. PubMed ID: 4292274
    [No Abstract]   [Full Text] [Related]  

  • 25. [Isolation of tubercle bacilli resistant to kanamycin or viomycine from tuberculous patients].
    Endo K; Takahashi M; Hashimoto H; Mitsuhashi S
    J Antibiot B; 1967 Aug; 20(4):251-3. PubMed ID: 4295238
    [No Abstract]   [Full Text] [Related]  

  • 26. The antimycobacterial activity of capreomycin.
    Lucchesi M
    Antibiot Chemother; 1970; 16():27-31. PubMed ID: 4108891
    [No Abstract]   [Full Text] [Related]  

  • 27. [In vitro antituberculous activity of lividomycin].
    Kobayashi F; Nagoya T; Eda J; Yoshimura Y
    Jpn J Antibiot; 1972 Dec; 25(6):360-6. PubMed ID: 4125073
    [No Abstract]   [Full Text] [Related]  

  • 28. Resistance system of Mycobacterium bovis B.C.B. to aminoglycoside- and peptide-antibiotics. Comparison of resistant phenotypes between Mycobacterium tuberculosis and Mycobacterium bovis.
    Tsukamura M
    Microbiol Immunol; 1980; 24(1):11-9. PubMed ID: 6153747
    [No Abstract]   [Full Text] [Related]  

  • 29. [Development of resistance of Mycobacterium tuberculosis to cycloserine, ethionamide, kanamycin, florimycin in experiments in vitro].
    Mkrtchian SV
    Antibiotiki; 1968 Oct; 13(10):907-10. PubMed ID: 4303355
    [No Abstract]   [Full Text] [Related]  

  • 30. [Studies on the effect of antituberculosis agents against tubercle bacilli in the resting state, using streptomycin-dependent strain (18-b). I. Studies in vitro].
    Ota Y
    Kekkaku; 1971 Aug; 46(8):295-301. PubMed ID: 4328204
    [No Abstract]   [Full Text] [Related]  

  • 31. [The proportion method of determination of the resistance of tubercle bacilli to ethionamide, cycloserine and viomycin].
    Zduńczyk-Pawelek H
    Gruzlica; 1966 Mar; 34(3):255-63. PubMed ID: 4287801
    [No Abstract]   [Full Text] [Related]  

  • 32. Experimental studies on the combined effect of kanamycin and viomycin.
    Hokama S
    Jpn J Tuberc Chest Dis; 1970 Jul; 16(1):62-9. PubMed ID: 4320009
    [No Abstract]   [Full Text] [Related]  

  • 33. Molecular analysis of kanamycin and viomycin resistance in Mycobacterium smegmatis by use of the conjugation system.
    Taniguchi H; Chang B; Abe C; Nikaido Y; Mizuguchi Y; Yoshida SI
    J Bacteriol; 1997 Aug; 179(15):4795-801. PubMed ID: 9244267
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Infectivity and pathogenicity of drug-resistant strains of tubercle bacilli studied by aerogenic infection of guinea pigs.
    Cohn ML; Davis CL
    Am Rev Respir Dis; 1970 Jul; 102(1):97-100. PubMed ID: 4316799
    [No Abstract]   [Full Text] [Related]  

  • 35. Investigation into the relationship of M ulcerans to M. buruli and other mycobacteria.
    Schröder KH
    Am Rev Respir Dis; 1975 Apr; 111(4):559-62. PubMed ID: 47730
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Clinical study on tuberactinomycin-N (TUM-N) and viomycin (VM) in retreatment of pulmonary tuberculosis (author's transl)].
    Kekkaku; 1974 Jul; 49(7):207-15. PubMed ID: 4372439
    [No Abstract]   [Full Text] [Related]  

  • 37. [A study on the tubercle bacillus drug-resistance test for RFP, EB, 1321 Th and KM (author's transl)].
    Xiao XL
    Zhonghua Jie He He Hu Xi Xi Ji Bing Za Zhi; 1981 Aug; 4(4):224-5. PubMed ID: 6804194
    [No Abstract]   [Full Text] [Related]  

  • 38. [Isolation of kanamycin or viomycin-resistant M. tuberculosis from tuberculous patients].
    Endo K; Takahashi M; Hashimoto H; Mitsuhashi S
    J Antibiot B; 1967 Feb; 20(1):1-5. PubMed ID: 4292905
    [No Abstract]   [Full Text] [Related]  

  • 39. Some experimental aspects of cross-resistance between capreomycin and viomycin.
    Algeorge G; Petre A
    Antibiot Chemother; 1970; 16():32-5. PubMed ID: 4108892
    [No Abstract]   [Full Text] [Related]  

  • 40. [Clinical comparison of capreomycin and kanamycin, with special reference to the effects of CPM in the KM-resistant cases].
    Saishin Igaku; 1968 Nov; 23(11):2400-4. PubMed ID: 4975235
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.